Orchid Pharma Limited · NSE:ORCHPHARMA
Orchid Pharma — Q3 FY23 Earnings Presentation
8 slides from Orchid Pharma's earnings presentation, Feb 17, 2023
Slide 1: Investors Presentation Q3 FY23 cover letter
OrchidPharma?’ — A Dhanuka Group Company — February 17, 2023 National Stock Exchange of India Limited, BSE Limited Exchange Plaza, Bandra Kurla Complex Phiroze Jeejeebhoy Towers, Bandra (E), Mumbai-400051 Dalal Street, Fort, Mumbai-400001 Symbol: ORCHPHARMA Scrip Code: 524372 ubject: Investors Prese
Slide 2: Welcome
OrchidPharma? — A Dhanuka Group C WELCOME
Slide 3: Financial Performance
Financial Performance (Rs/Crore) Q3-2022 Q3-2019 Change % 9M-31st Dec’22 9M-31st Dec’19 Change % Sales 159.8 129.5 +23% 456.0 396.5 +15% Other Income 8.9 7.0 +27% 17.7 18.8 -6% COGS 95.6 56.2 265.7 177.9 Employee Exp 16.7 22.6 -26% 49.0 65.3 -25% Other Exp 33.8 50.5 -33% 97.4 166.2 -41% EBITDA 22.6
Slide 4: Major Head of Savings
Major Head of Savings Nature of Expenses( Amt in Cr.) 9M-Dec.22 9M-Dec.19 Savings %Savings Consumption of Stores, Spares & Chemicals 8.77 18.94 10.17 53.7% Factory maintenance 10.75 15.36 4.60 30.0% Insurance 2.97 7.09 4.12 58.1% Consultancy & Professional Fees 2.21 8.97 6.75 75.3% Allowance for exp
Slide 5: Monetization of Assets
Monetization of Assets • Sale of Properties – 15 Cr. • Focus on realization of GST/MEIS Benefits • Receivable in Dec 19 ~ 80 Cr • Receivable in Dec 22 ~ 10 Cr • Sale of Loss Making IKKT Business:- • Loss in FY20 ~ 61 Cr • Loss in FY23 ~ NIL • Sale Proceeds:- • Cash ~ 113.91 Cr • 26% Equity ~ 45 Cr a
Slide 6: As a result
As a result • We have already reduced loan taken for acquisition by more than 70% 427 Crore ~ 120 Cr.
Slide 7: Key Developments Since last call
Key Developments Since last call • Launched Ceftazidime Avibactam for Emerging markets
Slide 8: Thanks
Thanks